[Special Stock] Pharmaresearch Plummets Amid MFDS Administrative Disciplinary Procedures

[Asia Economy Reporter Lee Seon-ae] Pharmaresearch's stock price is plummeting. It is interpreted as a result of the administrative disposition news from the Ministry of Food and Drug Safety.

As of 9:27 a.m. on the 10th, Pharmaresearch's stock price is trading at 77,600 won, down 11.01% compared to the previous trading day. It dropped to 73,000 won in the early session.

Meanwhile, on the same day, the Ministry of Food and Drug Safety announced that the Central Investigation Unit for Violations detected that two companies, Hugel and Pharmaresearch Bio, sold six botulinum toxin products domestically without obtaining national batch release approval, and has initiated administrative actions including cancellation of product approvals and procedures for recall and disposal of the relevant products.

The national batch release approval violation products detected this time are ▲Botulex Injection, Botulex Injection 50 units, Botulex Injection 150 units, Botulex Injection 200 units (Hugel) and ▲Lientox Injection 100 units, Lientox Injection 200 units (Pharmaresearch). In particular, in the case of Pharmaresearch, it was revealed that export-only drugs were sold domestically without approval for domestic sales, and a six-month suspension of all manufacturing operations is expected to be imposed.

This content was produced with the assistance of AI translation services.